|
MechanismSARS-CoV-2 S protein inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase I, Randomized, Double Blind, Placebo-controlled, Study of the Safety and Immunogenicity of mRNA-based COVID-19 Vaccine (COReNAPCIN) Produced by ReNAP Co. as Booster Dose in Healthy Population Aged 18-50 Years
100 Clinical Results associated with ReNAP Therapeutics
0 Patents (Medical) associated with ReNAP Therapeutics
100 Deals associated with ReNAP Therapeutics
100 Translational Medicine associated with ReNAP Therapeutics